Our focus on the patient drives everything we do and as a result, our path forward is clear:
John Maslowski, Chief Executive Officer
to develop game-changing cell and gene therapies for localized treatment of underserved disorders with high unmet medical needs.
Courtesy of debra—The Dystrophic Epidermolysis Bullosa Research Association of America and the Oliveira family. Used with permission.
Courtesy of debra—The Dystrophic Epidermolysis Bullosa Research Association of America and Mr. Feather. Used with permission.
Castle Creek Biosciences' D-Fi To Be Manufactured At In-House cGMP
Read MoreCompany manufacturing and distributing D-Fi at in-house, cGMP commercial-scale facility in greater Philadelphia area
Read MoreFirst Patient Treated in Trial Testing FCX-013 Gene Therapy for Localized Scleroderma
Read MoreStudy targets a chronic autoimmune skin disorder affecting approximately 50,000 patients in the U.S.
Read More